Pharmacokinetic and Pharmacodynamic Consequences of Liver‐Lung Crosstalk: Rethinking Dosing in Hepatopulmonary Syndrome and Portopulmonary Hypertension
Comprehensive Physiology · 2026-10 · 16 (5)
DOI: 10.1002/cph4.70276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Comprehensive Physiology, online erschienen am 09.10.2026. Verfasst von Mohssen Nassiri Toosi und 1 weiteren Autor:innen. Die Arbeit nennt 125 Literaturangaben.
Abstract (Originalsprache)
The liver–lung axis reflects bidirectional organ crosstalk. Hepatic dysfunction and portal hypertension can cause pulmonary vascular disease through two mechanisms: intrapulmonary microvascular vasodilation with hypoxemia (hepatopulmonary syndrome, HPS) or pulmonary arterial vasoconstriction and remodeling with elevated pulmonary artery pressure (portopulmonary hypertension, PoPH). Conversely, severe pulmonary disease can accelerate liver dysfunction, causing congestive hepatopathy and fibrosis. Despite growing recognition, mechanisms remain incompletely understood, and therapeutic implications are underappreciated in pharmacotherapy. HPS—the triad of liver disease, pulmonary vascular disease, and abnormal oxygenation—occurs in 5%–32% of adults with liver disease. PoPH affects 2%–8% of patients with portal hypertension and accounts for 5%–16% of World Health Organization (WHO) Group 1 pulmonary arterial hypertension cases. These syndromes create complex pharmacotherapy challenges: Patients may receive drugs for cirrhosis complications (beta‐blockers, diuretics, lactulose), pulmonary vascular disease (phosphodiesterase‐5 inhibitors, endothelin receptor antagonists, prostacyclin analogs), and thrombotic risk (anticoagulants), yet no dedicated dosing guidelines exist. Coagulation management exemplifies this complexity: The international normalized ratio (INR) reflects hepatic synthetic function and warfarin effect but does not predict bleeding risk in cirrhosis, where parallel loss of procoagulant and anticoagulant proteins creates a rebalanced hemostatic state that may tip toward hypercoagulability. Viscoelastic testing (thromboelastography) is therefore recommended to define the true coagulation phenotype, particularly perioperatively. This review examines the pharmacokinetic and pharmacodynamic consequences of liver–lung crosstalk and proposes a systematic framework for rational clinical dosing.
Zitieren
APA
Toosi, M. N., & Rad, N. K. (2026). Pharmacokinetic and Pharmacodynamic Consequences of Liver‐Lung Crosstalk: Rethinking Dosing in Hepatopulmonary Syndrome and Portopulmonary Hypertension. Comprehensive Physiology, 16(5). https://doi.org/10.1002/cph4.70276
Vancouver
Toosi MN, Rad NK. Pharmacokinetic and Pharmacodynamic Consequences of Liver‐Lung Crosstalk: Rethinking Dosing in Hepatopulmonary Syndrome and Portopulmonary Hypertension. Comprehensive Physiology. 2026;16(5). doi:10.1002/cph4.70276
BibTeX
@article{Toosi2026,
author = {Toosi, Mohssen Nassiri and Rad, Niloofar Khoshnam},
title = {Pharmacokinetic and Pharmacodynamic Consequences of Liver‐Lung Crosstalk: Rethinking Dosing in Hepatopulmonary Syndrome and Portopulmonary Hypertension},
journal = {Comprehensive Physiology},
year = {2026},
volume = {16},
number = {5},
doi = {10.1002/cph4.70276}
}
EUVIMED